# TriGemX Bio

> Late-stage migraine biotech developing elismetrep, an oral TRPM8 channel blocker.

## Why it is interesting

The $94 million financing funds an active pivotal program rather than early discovery. TriGemX is testing a mechanistically distinct migraine target after a positive Phase 2b study, with first Phase 3 results expected in mid-2027. The central risk is binary clinical and regulatory execution: elismetrep remains investigational and has not been approved.

## Profile

- **Latest funding:** Financing (stage undisclosed) — $94M (October 1, 2026)
- **Latest known valuation:** Not publicly disclosed
- **Total disclosed equity funding:** $94M
- **Stage:** growth
- **Status:** private
- **Industries:** biotech-life-sciences, healthtech
- **Coverage:** full
- **Last updated:** 2026-10-05T07:15:00Z
- **Latest funding investors:** The Column Group, TCGX, Viking Global Investors

## Key facts

- Closed $94 million of financing co-led by The Column Group, TCGX and Viking Global Investors.
- Two pivotal studies and a long-term safety study form the Phase 3 program.
- Relaunched from Kallyope as TriGemX Bio with a focused migraine strategy and new leadership.

## Funding history

- Financing (stage undisclosed) · $94M · October 1, 2026
  Source: https://trigemxbio.com/trigemx-bio-announces-94m-financing-and-initiation-of-phase-3-trials-for-elismetrep-a-potential-first-in-class-treatment-for-migraine/

## Investors in our directory

- https://venturecapitaltracker.com/fund/the-column-group
- https://venturecapitaltracker.com/fund/tcgx
- https://venturecapitaltracker.com/fund/viking-global-investors

## Related articles

- https://venturecapitaltracker.com/trigemx-bio-raises-94m-phase-3-migraine-trials

**By:** [Venture Capital Tracker](https://venturecapitaltracker.com/editorial-policy)
**Last updated:** October 5, 2026

**Editorial note:** AI tools assisted with research, structure, or drafting. Venture Capital Tracker retains human editorial responsibility for factual accuracy, relevance, and source quality before publication.

---
Source: https://venturecapitaltracker.com/startup/trigemx-bio